Thank you to all who joined Cantor’s Oncology, Hematology & HemeOnc Conference. Our first panel, “Novel Targets in Oncology: Risk vs. Reward” featured Dr. Todd Hobbs MD, CMO of Hepion Pharmaceuticals, Stone Paul A., CFO of IDEAYA Biosciences, Ron Bentsur, Chairman & CEO of Nuvectis Pharma, and Paul Levesque, President & CEO of Theratechnologies Inc. The panel was moderated by Li Watsek and Jennifer Kim.
• Hepion highlighted the potential of its lead candidate, Rencofilstat, a cyclophilin inhibitor, in development for NASH and HCC.
• IDEAYA discussed the positive Ph2 data from its lead asset, darovasertib (PKC inhibitor) + crizotinib in metastatic uveal melanoma. It spoke about how darovasertib combo in this indication thus far has unprecedented response and disease control rates compared to historical data. It discussed plans to bring the combo therapy into the metastatic setting as well as explore monotherapy in neo/adjuvant settings.
• Nuvectis highlighted the rationale and significant potential of its two novel precision medicine drug candidates: NXP800, an oral small molecule HSF1-pathway inhibitor, and NXP900, an oral small molecule SRC/YES1 kinase inhibitor which could address the shortcomings of other SRC/YES1 inhibitors.
• Theratechnologies walked through the potential advantages of its SORT1+ technology platform and pipeline of SORT1 receptor targeting cancer drugs, with lead candidate TH1902.
#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare